Dahlia Biosciences has developed RNA analysis tools that enable precision medicine research with CRISPR cell and tissue reagents. The company's reagent products will support research, drug development, and clinical diagnostic applications.
CEO: Un Kwon-Casado
Headquarters: Orinda, CA
Year Founded: 2017
Year Avestria First Invested: 2018 (Fund I)
Looking for a job opportunity at Dahlia? Click here.
Recent Press:
September 28, 2023: This article focuses on the new research completed by Sam Sternberg (one of the co-founders of Dahlia) and his postdoc, Chance Meers, PhD, which tracks the history of CRISPR, specifically the precursors to and the development of CRISPR/Cas9. The two scientists and their team also believe that, based on the evolution of CRISPR-Cas, there may be more “molecular scissors” that haven’t yet been discovered.
October 7, 2020: Emmanuelle Charpentier and Jennifer A. Doudna were announced as the 2020 Nobel Prize for Chemistry winners. The two scientists discovered CRISPR/Cas9: technology which is at the core of Dahlia Biosciences
November 29, 2019: “RCasFISH: CRISPR/dCas9-Mediated in Situ Imaging of mRNA Transcripts in Fixed Cells and Tissues”, a third-party publication, further validates Dahlia’s fixed-cell RNA detection technology usingRCas9, and it shows either superior performance and/or workflow to the existing competing methods: RNA FISH and RNAscope.
April 24, 2018: In this video from Indie Bio’s Demo Day, Un Kwon-Casado demonstrates Dahlia: how it works, what it can be used for, and what the company’s future goals are.